Hypocalcaemia and hospitalisation after initiation of bone-modifying agents in dialysis patients

Clicks: 3
ID: 338186
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #228 of 228 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 228 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background and Hypothesis Bone-modifying agents are associated with hypocalcaemia in dialysis patients, leading to serious adverse consequences. We examined factors associated with all-cause hospitalisation, longitudinal serum calcium trajectories by medication class, and baseline predictors of hypocalcaemia in dialysis patients initiating bone-modifying agents. Methods Using the JMDC hospital database, we identified dialysis patients newly prescribed bisphosphonates, denosumab, teriparatide, or romosozumab. Factors associated with all-cause hospitalisation were examined using Cox regression. Serum calcium trajectories were assessed over 90 days before and after treatment initiation. Factors associated with hypocalcaemia (corrected calcium < 8.0 mg/dL) within 90 days were analysed. Results Among 2 020 patients on dialysis, 1 057 (52.3%) received bisphosphonates; 693 (34.3%), denosumab; 136 (6.7%), teriparatide; and 134 (6.6%), romosozumab. Hospitalisation occurred in 425 patients, and recent hospitalisation and pretreatment lower corrected serum calcium levels were associated with hospitalisation, with no significant differences across medications. Among 374 patients with laboratory data, post-treatment hypocalcaemia occurred in 99 (26.5%). Persistent reductions in serum calcium levels were observed after initiating denosumab or romosozumab. Adjusted odds ratios (OR) for post-treatment hypocalcaemia were 13.4 (6.90–26.1) for denosumab and 8.09 (2.20–29.8) for romosozumab. Pretreatment calcium and parathyroid hormone levels were associated with post-treatment hypocalcaemia (adjusted ORs: 0.29 [0.18, 0.49] and 1.59 [1.05, 2.39], respectively). Conclusion In dialysis patients, denosumab and romosozumab were associated with a higher risk of post-treatment hypocalcaemia than bisphosphonates, and pretreatment lower calcium was associated with hospitalisation. Our findings highlight the importance of optimising parathyroid hormone management and enhancing calcium monitoring when initiating bone-modifying agents.
Reference Key
openalex_W7225129053 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Takahiro Imaizumi, Nobuhiro Nishibori, Masaki Okazaki, Koya Nagase, Yuko Asano, Yoshihisa Takada, Tomoko Handa, Daisuke Ito, Atsushi Hashizume, Shoichi Maruyama
Are you one of these authors? Claim your profile
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag364
URL
https://doi.org/10.1093/ckj/sfag364
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.